What’s Next for Ziopharm Oncology Inc (NASDAQ:ZIOP) After Having More Shares Shorted?

The stock of Ziopharm Oncology Inc (NASDAQ:ZIOP) registered an increase of 5.4% in short interest. ZIOP’s total short interest was 44.52 million shares in September as published by FINRA. Its up 5.4% from 42.24M shares, reported previously. With 1.84 million shares average volume, it will take short sellers 24 days to cover their ZIOP’s short positions. The short interest to Ziopharm Oncology Inc’s float is 28.92%.

The stock increased 3.99% or $0.19 during the last trading session, reaching $4.95. About 1.24 million shares traded. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 184.43% since September 11, 2018 and is uptrending. It has outperformed by 184.43% the S&P500.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $804.64 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It has a 5.13 P/E ratio. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 2 analysts covering ZIOPHARM Oncology (NASDAQ:ZIOP), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ZIOPHARM Oncology has $7.5 highest and $6.5000 lowest target. $7’s average target is 41.41% above currents $4.95 stock price. ZIOPHARM Oncology had 4 analyst reports since March 21, 2019 according to SRatingsIntel. The rating was maintained by Raymond James on Friday, August 23 with “Outperform”.

More notable recent ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news were published by: Finance.Yahoo.com which released: “ZIOPHARM Oncology, Inc. (ZIOP) Q2 2019 Earnings Call Transcript – Yahoo Finance” on August 09, 2019, also Seekingalpha.com with their article: “Ziopharm in-licenses IP from NCI for cancer cell therapies; shares up 2% after hours – Seeking Alpha” published on May 28, 2019, Nasdaq.com published: “Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma – Nasdaq” on August 08, 2019. More interesting news about ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) were released by: Nasdaq.com and their article: “Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine – Nasdaq” published on August 14, 2019 as well as Globenewswire.com‘s news article titled: “Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting – GlobeNewswire” with publication date: June 02, 2019.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.